coagulation factor XIII (Tretten®)

OFFICE  ADMINISTRATION

Indications for Prior Authorization:

  • Prophylaxis of bleeding episodes in adults and children with congenital Factor XIII A-subunit deficiency

The drug is not approved for any use not mentioned above including:

  • Congenital Factor XIII B-subunit deficiency

Dosing:

  • The recommended dose is 35 IU/kg body weight by IV injection once monthly

Approval:

One year


  

Last review date: May 1, 2014

Friday, July 19 Breaking News: A widespread computer software outage is impacting systems across the globe. Health care services in Northern California are reporting some disruption. WHA encourages members to call ahead to your provider if you have an appointment scheduled for today or this weekend.